Gonzalez Ricardo J, Kudchadkar Ragini, Rao Nikhil G, Sondak Vernon K
Ochsner J. 2010 Summer;10(2):108-16.
Adjuvant therapy is widely used in melanoma cases because recurrence of disease after surgery is notoriously difficult to treat and usually results in the patient's death. Clinicians have a fundamental influence on the patient's decisions regarding adjuvant therapy, beginning with providing a clear understanding of the risk of specific types of recurrence based on features of the primary melanoma and status of the sentinel nodes and then explaining the morbidity of surgical treatment with and without adjuvant therapy. This review summarizes the role of adjuvant immunotherapy and radiation in the treatment of high-risk melanoma. We review the risks of specific types of recurrence as well as the potential oncologic benefits and relevant toxicities of available adjuvant therapies for high-risk melanoma.
辅助治疗在黑色素瘤病例中被广泛应用，因为手术后疾病复发 notoriously 难以治疗，且通常会导致患者死亡。临床医生对患者关于辅助治疗的决策具有根本性影响，首先要基于原发性黑色素瘤的特征和前哨淋巴结状态，清晰地向患者说明特定类型复发的风险，然后解释进行或不进行辅助治疗时手术治疗的发病率。本综述总结了辅助免疫治疗和放疗在高危黑色素瘤治疗中的作用。我们回顾了特定类型复发的风险，以及高危黑色素瘤现有辅助治疗的潜在肿瘤学益处和相关毒性。
